We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current KYTX market cap is 380.47M. The company's latest EPS is USD -1.4787 and P/E is -6.44.
Quarter End | Dec 2023 | Mar 2024 | |
---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 0 | 0 | |
Operating Income | -21.38M | -29.36M | |
Net Income | -20.67M | -26.69M |
Year End December 30 2023 | 2021 | 2022 | 2023 |
---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 5.66M | 7.03M | 0 |
Operating Income | -26.35M | -29.38M | -62.41M |
Net Income | -26.35M | -28.89M | -60.37M |
Quarter End | Dec 2023 | Mar 2024 | |
---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 75.2M | 389.98M | |
Total Liabilities | 26.02M | 28.99M | |
Total Equity | -131.4M | 360.99M |
Year End December 30 2023 | 2021 | 2022 | 2023 |
---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 85.49M | 66.92M | 75.2M |
Total Liabilities | 23.02M | 20.25M | 26.02M |
Total Equity | -46.25M | -74M | -131.4M |
Quarter End | Dec 2023 | Mar 2024 | |
---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | |
Operating | -52.41M | -25.53M | |
Investing | -8.79M | -122.88M | |
Financing | 58.12M | 338.05M |
Year End December 30 2023 | 2021 | 2022 | 2023 |
---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | |
Operating | -22.16M | -36.11M | -52.41M |
Investing | -1.29M | -14.1M | -8.79M |
Financing | 72.52M | 11.88M | 58.12M |
Market Cap | 380.47M |
Price to Earnings Ratio | -6.44 |
Price to Sales Ratio | 0 |
Price to Cash Ratio | 11.22 |
Price to Book Ratio | 7.9 |
Dividend Yield | - |
Shares Outstanding | 40.82M |
Average Volume (1 week) | 625.12k |
Average Volume (1 Month) | 482.54k |
52 Week Change | -72.79% |
52 Week High | 35.01 |
52 Week Low | 8.80 |
Spread (Intraday) | 1.93 (17.99%) |
Company Name | Kyverna Therapeutics Inc |
Address |
3500 s dupont hwy dover, delaware 19901 |
Website | https://kyvernatx.com |
Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions